LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion.
Disclaimer:
This site is intended for discussions about LEO Pharma and the various initiatives LEO Pharma is involved in. Due to regulations, discussions about pharmaceutical products are not allowed on this site. All content must be factual and non-promotional.
LEO Pharma reserves the right to moderate or remove any content that may be inconsistent with legislation, industry ethics and regulations and LEO Pharma’s values, including:
- profane or vulgar language
- insulting or offensive comments, such as displays of racism, calls to violence, hate propaganda, etc.
- commercial or political advertising
- copyright infringements, or any violation of the rights of external parties
- automatically-generated content i.e. spam
- wrong/false statements
For more information about our social media principles, please visit https://www.leo-pharma.com/social-media-principles
